A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 13 Jun 2009 Results presented at thye 10th Annual Congress of the European League Against Rheumatism
- 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry, record no. ACTRN12605000785606).
- 14 Jun 2008 Primary endpoint met and results will be presented at the Annual Congress of the European League Against Rheumatism (EULAR) according to a Bristol-Myers Squibb media release.